Patent ID: 6197580
Filing Date: 2001-03-06
Classification: A61P,C07K,C12Q

Abstract:
An isolated nucleic acid comprising a trans-activator binding site nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to an Sp-1 binding site, wherein the isolated nucleic acid is selected from the group consisting of:(a) about a 7 kb genomic DNA 5' flanking region of a .beta..sub.3 -adrenergic receptor (.beta..sub.3 -AR) transcription start site,(b) a deletion construct of a 7 kb genomic DNA located upstream of a .beta..sub.3 -AR transcription start site;(c) a nucleic acid wherein the sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQID NO:1) is located 5' to the Sp-1 binding site relative to a transcription start site; and(d) a nucleic acid comprising a heterologous coding sequence operatively associated with a promoter and operatively associated with the nucleotide sequence that is (greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to the Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.